alexa Abstract | Novel Agents for the Treatment of Pancreatic Cancer

JOP. Journal of the Pancreas
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Metastatic pancreatic cancer continues to be a difficult disease to treat because of its aggressive nature, advanced stage atpresentation and lack of treatment options. There is a need for the development of new agents directed against novel targetsto improve outcomes for these patients. At the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal CancersSymposium phase I/II trials provided information on three novel strategies for treating metastatic pancreatic cancer.Immunotherapy in the form of a vaccine (GVAX) followed with an immune stimulator (CRS-207) showed extended survival(Abstract #177). A monoclonal antibody (NEO-102) targeting MUC5AC also showed activity and was well tolerated (Abstract#243). A heat shock protein 90 (HSP90) inhibitor (ganetespib) showed modest effects but was well tolerated making itavailable for use with conventional chemotherapy (Abstract #297). The details of these presentations will be discussed.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Muhammad Wasif Saif Gregory T Brennan Valerie Relias

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version